All In Biotech

Drug Trial Radar · NCT03699956

RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer

A Phase 3, Controlled, Open-label, Randomized Study of RRx-001 Administered Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Mar 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

18

Actual

Start

Dec 24, 2018

Primary completion

Aug 11, 2022

Study completion Mar 1, 2024

Sponsor

Lead sponsor
EpicentRx, Inc.Industry
Sponsor type
Industry
First posted
Oct 9, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 79 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 3 study aims to find out whether RRx-001 + platinum chemotherapy is more effective than platinum chemotherapy alone in 3rd line or beyond small cell cancer.

Conditions

  • Carcinoma, Small Cell Lung

Interventions

  • RRx-001 + eLOOP DeviceCombination product

    RRx-001 is a small molecule anticancer drug which is mixed with patient's own blood using the eLOOP device

  • Cisplatin/carboplatin plus etoposideDrug

    Standard of care platinum doublet chemotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free SurvivalTime frame: Estimated up to 12 Months

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Centura Health Research Center

    Denver, Colorado

  • Mid Florida Hematology and Oncology Center

    Orange City, Florida

  • AdventHealth Hematology and Oncology

    Orlando, Florida

  • H. Lee Moffitt Cancer Center & Research Institute, Inc.

    Tampa, Florida

  • Rush University Medical Center

    Chicago, Illinois

  • Cotton O'Neil Clinical Research Center.Hematology & Oncology

    Topeka, Kansas

  • The University of Kansas Cancer Center

    Westwood, Kansas

  • Norton Cancer Institute, Norton Healthcare Pavilion

    Louisville, Kentucky

  • University of Maryland Marlene and Stewart Greenbaum Comprehensive Cancer Center

    Baltimore, Maryland

  • University of Mississippi Medical Center

    Jackson, Mississippi

  • Washington University School of Medicine - Siteman Cancer Center

    St Louis, Missouri

  • Oncology Hematology West PC dba Nebraska Cancer Specialists

    Omaha, Nebraska

  • Dartmouth-Hitchcock Medical Center

    Lebanon, New Hampshire

  • Stephenson Cancer Center

    Oklahoma City, Oklahoma

  • Tennessee Cancer Specialists

    Knoxville, Tennessee

  • Millennium Oncology

    Houston, Texas

  • HOPE Cancer Center of East Texas

    Tyler, Texas

  • Utah Cancer Specialist

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.